Enhancing Virus-Specific Immunity by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection

English version České info

Hepatitis B virus (HBV) persistence is facilitated by exhaustion of CD8 T cells that express the inhibitory receptor programmed cell death-1 (PD-1). Improvement of the HBV-specific T cell function has been obtained in vitro by inhibiting the PD-1/PD-ligand 1 (PD-L1) interaction. In this study, we examined whether in vivo blockade of the PD-1 pathway enhances virus-specific T cell immunity and leads to the resolution of chronic hepadnaviral infection in the woodchuck model. The woodchuck PD-1 was first cloned, characterized, and its expression patterns on T cells from woodchucks with acute or chronic woodchuck hepatitis virus (WHV) infection were investigated. Woodchucks chronically infected with WHV received a combination therapy with nucleoside analogue entecavir (ETV), therapeutic DNA vaccination and woodchuck PD-L1 antibody treatment. The gain of T cell function and the suppression of WHV replication by this therapy were evaluated. We could show that PD-1 expression on CD8 T cells was correlated with WHV viral loads during WHV infection. ETV treatment significantly decreased PD-1 expression on CD8 T cells in chronic carriers. In vivo blockade of PD-1/PD-L1 pathway on CD8 T cells, in combination with ETV treatment and DNA vaccination, potently enhanced the function of virus-specific T cells. Moreover, the combination therapy potently suppressed WHV replication, leading to sustained immunological control of viral infection, anti-WHs antibody development and complete viral clearance in some woodchucks. Our results provide a new approach to improve T cell function in chronic hepatitis B infection, which may be used to design new immunotherapeutic strategies in patients.

Vyšlo v časopise: Enhancing Virus-Specific Immunity by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection. PLoS Pathog 10(1): e32767. doi:10.1371/journal.ppat.1003856
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003856

Souhrn

Zdroje

1. JanssenHL, van ZonneveldM, SenturkH, ZeuzemS, AkarcaUS, et al. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123–129.

2. LauGK, PiratvisuthT, LuoKX, MarcellinP, ThongsawatS, et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682–2695.

3. LocarniniS, MasonWS (2006) Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44: 422–431.

4. ZoulimF, LocarniniS (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593–1608 e1591–1592.

5. KlenermanP, HillA (2005) T cells and viral persistence: lessons from diverse infections. Nat Immunol 6: 873–879.

6. von HerrathMG, BergerDP, HomannD, TishonT, SetteA, et al. (2000) Vaccination to treat persistent viral infection. Virology 268: 411–419.

7. DikiciB, KalayciAG, OzgencF, BosnakM, DavutogluM, et al. (2003) Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 22: 345–349.

8. NevensF, RoskamsT, Van VlierbergheH, HorsmansY, SprengersD, et al. (2003) A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38: 1289–1296.

9. WherryEJ, BlattmanJN, AhmedR (2005) Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 79: 8960–8968.

10. NisiiC, TempestilliM, AgratiC, PocciaF, TocciG, et al. (2006) Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. J Hepatol 44: 475–483.

11. BarberDL, WherryEJ, MasopustD, ZhuB, AllisonJP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682–687.

12. MaierH, IsogawaM, FreemanGJ, ChisariFV (2007) PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 178: 2714–2720.

13. VeluV, TitanjiK, ZhuB, HusainS, PladevegaA, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206–210.

14. FinnefrockAC, TangA, LiF, FreedDC, FengM, et al. (2009) PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol 182: 980–987.

15. FreemanGJ, WherryEJ, AhmedR, SharpeAH (2006) Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203: 2223–2227.

16. BoniC, FisicaroP, ValdattaC, AmadeiB, Di VincenzoP, et al. (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81: 4215–4225.

17. DayCL, KaufmannDE, KiepielaP, BrownJA, MoodleyES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.

18. TrautmannL, JanbazianL, ChomontN, SaidEA, GimmigS, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12: 1198–1202.

19. PetrovasC, CasazzaJP, BrenchleyJM, PriceDA, GostickE, et al. (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203: 2281–2292.

20. PennaA, PilliM, ZerbiniA, OrlandiniA, MezzadriS, et al. (2007) Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45: 588–601.

21. PilliM, ZerbiniA, PennaA, OrlandiniA, LukasiewiczE, et al. (2007) HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133: 1132–1143.

22. HaSJ, MuellerSN, WherryEJ, BarberDL, AubertRD, et al. (2008) Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 205: 543–555.

23. LuM, YaoX, XuY, LorenzH, DahmenU, et al. (2008) Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol 82: 2598–2603.

24. ZhangE, ZhangX, LiuJ, WangB, TianY, et al. (2011) The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS One 6: e26196.

25. BurshtynDN, LamAS, WestonM, GuptaN, WarmerdamPA, et al. (1999) Conserved residues amino-terminal of cytoplasmic tyrosines contribute to the SHP-1-mediated inhibitory function of killer cell Ig-like receptors. J Immunol 162: 897–902.

26. SidorenkoSP, ClarkEA (2003) The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol 4: 19–24.

27. ZhangZ, ZhangJY, WherryEJ, JinB, XuB, et al. (2008) Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134: 1938–1949, 1949 e1931–1933.

28. FrankI, BuddeC, FiedlerM, DahmenU, ViazovS, et al. (2007) Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol 81: 7156–7163.

29. KosinskaAD, JohrdenL, ZhangE, FiedlerM, MayerA, et al. (2012) DNA Prime-Adenovirus Boost Immunization Induces a Vigorous and Multifunctional T-Cell Response against Hepadnaviral Proteins in the Mouse and Woodchuck Model. J Virol 86: 9297–9310.

30. KosinskaAD, ZhangE, JohrdenL, LiuJ, SeizPL, et al. (2013) Combination of DNA prime–adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS pathogens 9: e1003391.

31. WherryEJ, HaSJ, KaechSM, HainingWN, SarkarS, et al. (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670–684.

32. WebsterGJ, ReignatS, BrownD, OggGS, JonesL, et al. (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78: 5707–5719.

33. MainiMK, BoniC, LeeCK, LarrubiaJR, ReignatS, et al. (2000) The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269–1280.

34. PolS, DrissF, MichelML, NalpasB, BerthelotP, et al. (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344: 342.

35. PolS, NalpasB, DrissF, MichelML, TiollaisP, et al. (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34: 917–921.

36. YalcinK, AcarM, DegertekinH (2003) Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31: 221–225.

37. HelZ, VenzonD, PoudyalM, TsaiWP, GiulianiL, et al. (2000) Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 6: 1140–1146.

38. TryniszewskaE, NacsaJ, LewisMG, SilveraP, MontefioriD, et al. (2002) Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 169: 5347–5357.

39. FisicaroP, ValdattaC, MassariM, LoggiE, BiasiniE, et al. (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138: 682–693, 693 e681–684.

40. BlackburnSD, ShinH, FreemanGJ, WherryEJ (2008) Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 105: 15016–15021.

41. FerraroB, MorrowMP, HutnickNA, ShinTH, LuckeCE, et al. (2011) Clinical applications of DNA vaccines: current progress. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 53: 296–302.

42. TopalianSL, HodiFS, BrahmerJR, GettingerSN, SmithDC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.

43. BrahmerJR, TykodiSS, ChowLQ, HwuWJ, TopalianSL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.

44. SchurichA, KhannaP, LopesAR, HanKJ, PeppaD, et al. (2011) Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53: 1494–1503.

45. WuW, ShiY, LiS, ZhangY, LiuY, et al. (2012) Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. European journal of immunology 42: 1180–1191.

46. LiFJ, ZhangY, JinGX, YaoL, WuDQ (2013) Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunology letters 150: 116–122.

47. LanfordRE, GuerraB, ChavezD, GiavedoniL, HodaraVL, et al. (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144: 1508–1517, 1517 e1501–1510.

48. CrettazJ, OtanoI, Ochoa-CallejeroL, BenitoA, PanedaA, et al. (2009) Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol 83: 2663–2674.

49. LuM, HilkenG, KruppenbacherJ, KemperT, SchirmbeckR, et al. (1999) Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol 73: 281–289.

50. LuM, IsogawaM, XuY, HilkenG (2005) Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol 79: 6368–6376.

51. LuM, LohrengelB, HilkenG, KemperT, RoggendorfM (2002) Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J Virol 76: 58–67.

52. ZhangX, MengZ, QiuS, XuY, YangD, et al. (2009) Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol 11: 1624–1637.

53. ColonnoRJ, GenovesiEV, MedinaI, LambL, DurhamSK, et al. (2001) Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. The Journal of infectious diseases 184: 1236–1245.